Spiolto Respimat Warnings

Concise Prescribing Info Bahasa Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Side Effects Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Warnings

ASTHMA-RELATED DEATH: Long-acting beta₂-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large, placebo-controlled US study that compared the safety of another long-acting beta₂-adrenergic agonist (salmeterol) to placebo added to patients' usual asthma therapy, showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including olodaterol, one of the active ingredients in SPIOLTO RESPIMAT.
SPIOLTO RESPIMAT is only indicated for COPD. The safety and efficacy of SPIOLTO RESPIMAT in patients with asthma have not been established. SPIOLTO RESPIMAT is not indicated for the treatment of asthma.

Manufacturer:

Boehringer Ingelheim